Navigation Links
EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
Date:4/14/2008

his high profile session. ENMD-2076 is an exciting compound with demonstrated single-agent activity against a broad range of tumor types. EntreMed recently commenced a Phase 1, dose-escalation study with ENMD-2076 in advanced cancers and plans to initiate a second Phase 1 study in hematological cancers later in 2008."

To view a copy of Dr. Bray's presentation, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, whi
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
10. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... pharmaceutical market is one of the most attractive in ... size, plus a growing economy and increasing government investment ... International. The Russian market is set to grow at ... growth estimates around 10-15% annually reaching an approximate market ... Green Cross Green Cross provides total healthcare ...
(Date:3/25/2015)... Optimal Research, LLC has been nominated as ... "Best Clinical Site or Trial Network". This ... selected as a nominee in this ViE award category ... distinction in 2014. The ViE awards were created to ... positive contributions of companies and individuals in the vaccine ...
(Date:3/25/2015)... March 25, 2015 Laboratory workers ... Balances and Analytical Balances to get best-performing features ... of weighing balances from the trusted brand include: ... increase your efficiency by providing a large ... samples. Weighing modes include parts counting, percent weighing, ...
(Date:3/25/2015)... An increase of awareness related to benefits ... food nutrients, regulatory changes and concerns related to consumer ... for natural astaxanthin over the past few years. Producers ... capacities to satisfy the rising demand. , The ... (used in nutraceuticals, aqua feed, food and beverages and ...
Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... Kan., Nov. 16, 2011 The Kansas Bioscience Authority ... ended June 30, and cumulative outcomes since the KBA,s ... investments, are reported annually based on information provided by ... full-time jobs created by bioscience companies in Kansas; ...
... Livestream Info ... http://thehill.com/video/in-the-news/193083-livestreaming-genetic-testing-briefing . , ... is redefining cancer treatment, and the pace of discovery promises ... conditions. That will be among the topics of discussion today ...
... 2011 Nektar Therapeutics (NASDAQ: NKTR ... a next-generation topoisomerase I inhibitor, at the 2011 ... being held in San Francisco, California.  The preclinical ... pegylated liposomal doxorubicin (PLD) in vivo has strong ...
Cached Biology Technology:Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 2Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 3Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 3NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 4NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 5NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 6
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... events, two comprehensive, collaborative projects that include the work ... Natural History will grace the covers of the journals ... Science, herpetologist and Associate Dean of Science Christopher Raxworthy ... more typical few keystone species, to determine a conservation ...
... be so old that dinosaurs once lumbered along its rim, ... Colorado at Boulder and the California Institute of Technology. ... show the Grand Canyon may have formed more than 55 ... million to 50 million years. The researchers gathered evidence ...
... the evolutionary history of animals indicates that Earth,s first ... from fossils and studies of living animals--was probably significantly ... which was funded by the National Science Foundation (NSF), ... issue of Nature. Using new high-powered technologies for analyzing ...
Cached Biology News:AMNH scientists grace Science & Nature covers 2AMNH scientists grace Science & Nature covers 3Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3And the first animal on Earth was a... 2And the first animal on Earth was a... 3
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... contain a proprietary high-performance desalting resin, exclusive ... protein-recovery characteristics compared to other commercially available ... g/ml of protein can be processed, providing ... of salts and other small molecules ( ...
Biology Products: